Showing 27 results

Charlotte Bevan

Using a newly discovered type of genetic material to unlock treatments for prostate cancer

Professor Bevan and Dr Fletcher will investigate the role of newly discovered molecules in advanced prostate cancer becoming treatment resistant, with the goal of developing new drugs.

Professor Amanda Swain with researchers

Testing precision medicine in mini prostate cancer tumours

We’re funding Dr Swain to create mini prostate cancer tumours in the lab to look for genes that allow tumours to grow, respond to treatment and become resistant to treatment. The project could go on to inform precision medicine trials for advanced prostate cancer treatments.

Using sugars to diagnose aggressive prostate cancer

Professor Mendes aims to develop a new test, that can be used alongside the PSA test, to accurately determine which men have aggressive prostate cancer and need immediate therapy, and which men can be spared unnecessary treatments.

Scientists Newcastle

Hitting the sweet spot

Dr Munkley will investigate why the loss of sugar groups on the outside of the cell leads to prostate cancer cell death, and whether she can use existing anti-glycosylation drugs to exploit this as a potential new treatment for aggressive prostate cancer.

Keun and Rana

Making sense of big data on small molecules

Dr Hector Keun and his PhD student will unlock the power of microRNAs to distinguish aggressive cancers from low-risk ones and to tell us which is likely to be the best treatment for an individual man’s cancer.

Developing a non-invasive assay for the detection of prostate cancer

Dr Feber and his team aim to improve the way that prostate cancer is diagnosed and monitored. They’ve developed a test that looks at prostate cancer specific DNA modifications that can be detected in the blood of men with prostate cancer.

Chris Parker

A prostate cancer risk prediction tool for primary care practice

Funded research by Dr Chris Parker of the Institute of Cancer Research which looks to develop a risk assessment tool to give a better indication of a man’s risk of having aggressive prostate cancer.

Dr Hayley Whitaker

Using imaging, blood and urinary biomarkers to improve the diagnosis of aggressive prostate cancer

Funded research by Dr Hayley Whitaker of University College London which aims to define which patients will benefit from diagnostic multiparametric (mp)MRI before biopsy and to improve the performance of the mpMRI itself.

Assessing prostate cancer aggressiveness using a new type of non-invasive imaging

Funded research by Dr Ferdia Gallagher of University of Cambridge using a new type of non-invasive imaging to determine how aggressive prostate cancer is in individual patients.

Dr Hayley Whitaker

Combining markers with imaging for improved diagnosis of aggressive prostate cancer

Funded research by Dr Hayley Whitaker of University College London looking at combining markers with imaging to improve the diagnosis and treatment of prostate cancer in a way that can easily be adopted by the NHS.

MULTIPROS: using imaging to improve prostate cancer diagnosis

Improved technology for imaging prostate cancer, like mpMRI, has helped transform diagnosis of the disease. Professor Nabi wants to add to the evidence that prostate imaging technologies should be made widely available to continue to improve diagnosis of the disease.

Finding metabolic target genes in prostate cancer

Turning microRNAs, a new type of genetic material, into a way to treat advanced prostate cancer

Alterations in a man's genetic make-up which lead to aggressive prostate cancer

Funded research by Prof. Rosalind Eeles and Dr Zsofia Kote-Jarai of the Institute of Cancer Research into genetic changes in the DNA repair genes and their relationship with aggressive disease.

Identification of genetic changes that drive aggressive prostate cancer progression

Looking for genetic changes in men with prostate cancer that are able to drive the disease to a more aggressive stage.

Developing imaging methods to better assess the spread of prostate cancer to other body sites

Funded research by Dr Shonit Punwani of University College London into whether whole body MRI can be used as a more sensitive means of detecting metastasis.

Search for a new way to identify and treat advanced prostate cancer

Funded research by Dr Tania Maffucci of Queen Mary University of London into the implications of a recently discovered protein found mainly in prostate cancer cells.

Prohibitin: a new way to slow prostate cancer growth

Professor Bevan and her team have been studying prohibitin , a protein that controls prostate cancer growth, since 2004. In this project, they have found a way to manipulate prohibitin levels, and turn it into a potential treatment for prostate cancer.

A new approach to testing markers of prostate cancer

Funded research by Dr Chris Parker of the Institute of Cancer Research into better ways of distinguishing between aggressive and indolent forms of prostate cancer using samples from 714 men undergoing a template mapping biopsy.

Improved initial diagnosis and localisation of prostate cancer

Funded research by Prof Reyer Zwiggelaar of Aberystwyth University into combining MRI with ultrasound information to improve diagnosis and localisation.

A new method to detect bone cancers that have spread from the prostate (metastases) and monitor their response to treatment

Funded research by Prof. Gary Cook of St Thomas' Hospital, London into the use of 99mTc maraciclatide SPECT imaging to detect and measure the treatment response of bone metastases.

How androgens drive prostate cancer cell growth

Funded research by Professor David Elliott of Newcastle University into the effect of androgen on gene expression in prostate cancer cells, how the affected genes influence progression and whether this basis can be used to diagnose different types of the disease.

Ultrasound characterisation of tissues' stiffness in prostate cancer

Funded research by Mr Ghulam Nabi of Dundee University into new ways of using ultrasound to to examine the relative stiffness of tissues within the prostate, and therefore differentiate between aggressive and non-aggressive cancers.

Genetic tests that can be performed on blood to allow the differentiation of aggressive from low activity prostate cancer and the identification of changes that cause resistance in patients receiving treatment

Funded research by Dr Gerhardt Attard of the Institute of Cancer Research into developing tests to identify genetic abnormalities in circulating material that will help distinguish between aggressive and non-aggressive cancers.

Insight into the mechanisms linking the metabolism of fat to prostate cancer progression

Funded research by Dr Wells and Dr Van Hemelrijck of King's College London into the whether fat metabolism can be used to indicate whether a tumour is aggressive or indolent.

Aldehyde dehydrogenases in prostate cancer

Funded research by Dr Klaus Pors of Bradford University into whether certain enzymes associated with the growth and spread of cancer cells can be used to more accurately diagnose aggressive forms of prostate cancer.